Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference

Rhea-AI Summary

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) announced its participation in two upcoming healthcare conferences in New York: the Guggenheim 2022 Immunology & Neurology Conference on November 14-15 and the Stifel 2022 Healthcare Conference on November 15-16. As a clinical-stage biopharmaceutical company, Reata focuses on developing innovative therapeutics for serious diseases, with lead candidates omaveloxolone and bardoxolone targeting the Nrf2 transcription factor to combat inflammation and oxidative stress. However, their safety and efficacy remain unverified.

Positive

• Participation in key healthcare conferences may enhance visibility and investor interest.
• Focus on developing therapies targeting critical molecular pathways could indicate potential for future growth.

Negative

• The investigational status of omaveloxolone and bardoxolone means safety and efficacy have not been established, posing risks to future approval and market entry.

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology & Neurology Conference on November 14 – 15, 2022 in New York, NY, and will participate in the Stifel 2022 Healthcare Conference on November 15 – 16, 2022 in New York, NY.

About Reata

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, omaveloxolone and bardoxolone methyl (“bardoxolone”), target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Omaveloxolone and bardoxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop, and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006154/en/

Reata Pharmaceuticals, Inc.

(972) 865-2219

https://www.reatapharma.com/

Investor Relations & Media Relations:

John Hunter ir@reatapharma.com

Wendy Segal media@reatapharma.com

https://www.reatapharma.com/contact-us/

Source: Reata Pharmaceuticals, Inc.

FAQ

When will Reata Pharmaceuticals participate in the Guggenheim 2022 Immunology & Neurology Conference?

Reata Pharmaceuticals will participate in the Guggenheim 2022 Immunology & Neurology Conference on November 14-15, 2022.

What is the significance of Reata's participation in the Stifel 2022 Healthcare Conference?

Reata's participation in the Stifel 2022 Healthcare Conference on November 15-16, 2022, may provide important networking and exposure opportunities.

What are the lead candidates of Reata Pharmaceuticals?

Reata's lead candidates are omaveloxolone and bardoxolone, which target the Nrf2 transcription factor.

Are omaveloxolone and bardoxolone approved drugs?

No, omaveloxolone and bardoxolone are investigational drugs, and their safety and efficacy have not been established.

What risks does Reata Pharmaceuticals face regarding its drug candidates?

Reata faces risks related to the unverified safety and efficacy of its candidates, which may impact their regulatory approval and market potential.